Skip to main content
Rize RecoveryThe Newsroom
Harm Reduction· Article

Xylazine: What Frontline Workers Need to Know

The veterinary sedative now adulterating the U.S. fentanyl supply complicates overdose response — and naloxone is no longer enough.

ByThe Rize NewsroomApril 28, 20261 min readNovel & Emerging Psychoactives

Xylazine, a veterinary α-2 adrenergic agonist not approved for human use, has spread from Philadelphia’s drug supply in the late 2010s to every state in the country by 2026. It is now detected in roughly 23% of fentanyl seizures nationally, with regional rates exceeding 50%.

Why this matters: xylazine is not reversed by naloxone. While naloxone still treats the fentanyl component of an overdose, xylazine produces sedation and respiratory depression that persists after opioid effects are reversed.

What field workers see

  • Prolonged sedation despite multiple naloxone doses
  • Severe wound complications — necrotic skin lesions, often in unusual sites unrelated to injection
  • Withdrawal that does not respond to standard opioid withdrawal protocols

What changes in protocol

  1. Continue naloxone administration — the fentanyl is still the immediate killer
  2. Maintain airway and oxygenation — xylazine respiratory depression may persist
  3. Always call EMS for suspected xylazine-involved overdose
  4. Wound care education — early intervention prevents amputation

Treatment

There is no FDA-approved medication for xylazine withdrawal. Off-label clonidine, tizanidine, and dexmedetomidine show promise. Xylazine wounds require dedicated wound-care protocols often beyond what street-medicine teams are equipped for.

— Health alerts: SAMHSA Xylazine Resources, HHS Xylazine Designation.

Sources Cited

  1. 01.A
    SAMHSA Xylazine Resource PageSAMHSA
  2. 02.A
    HHS Xylazine Designation MemoHHS

Filed Under

harm-reductionbiologytreatmentOverdoseNaloxoneFentanyl Test StripsGovernment Data

Continue reading

More from this section

Harm Reduction

69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.

CDC provisional data projects 69,973 overdose deaths for 2025—a 13.9% decline. The same spring, SAMHSA ended federal funding for fentanyl test strips. The drug supply has never been more dangerous.

Harm Reduction

Responding to the Emerging Threat of Xylazine

On April 24, SAMHSA banned federal funding for fentanyl, xylazine, and medetomidine test strips for public distribution — precisely as the June 2026 Labcorp report shows medetomidine in 91% of Philadelphia's fentanyl supply. The policy contradiction that kills people who use drugs.

Harm Reduction

The Drug Inside the Drug: How Medetomidine Is Breaking Every Overdose Response Playbook

Medetomidine, a veterinary sedative 200 times more potent than xylazine, has displaced xylazine in Philadelphia's fentanyl supply and is confirmed in nine states. It produces sedation that naloxone cannot reverse, withdrawal that requires ICU-level care in 91% of hospitalized patients, and clinical presentations that emergency departments are consistently misidentifying.